ELMMB logo
Facebook logo Twitter logo
MHRA Drug Safety Updates


MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

application/pdfMHRA Drug Safety Update November_2023-DSU.pdf (274KB)23/11/2023Download
 Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products. Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions... 
application/pdfMHRA Drug safety Update October_2023.pdf (275KB)23/11/2023Download
application/pdfMHRA Drug Safety Update September-2023-PDF.pdf (267KB)27/09/2023Download
 Statins: very infrequent reports of myasthenia gravis, Page 2 Fluoroquinolone antibiotics: suicidal thoughts and behaviour  
application/pdfMHRA Drug Safety Update August 2023 DSU.pdf (293KB)30/08/2023Download
 Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects. Methotrexate: advise patients to take precautions in the sun to avoid ... 
application/pdfMHRADrug safety Update July2023 PDF.pdf (212KB)24/07/2023Download
 Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia. Codeine linctus: public consultation on the proposal to... 
application/pdfMHRA Drug Safety Update June 2023-DSU-PDF.pdf (325KB)28/06/2023Download
 Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia; Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged... 
application/pdfMHRA Drug Safety Update May 2023-DSU.pdf (327KB)25/05/2023Download
 Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment page 2 :Glucose solutions: recommendations to minimise the risks... 
application/pdfMHRA Drug Safety Update April 2023 DSU.pdf (345KB)26/04/2023Download
 Isotretinoin (Roaccutane▼): new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years. Janus kinase (JAK)... 
application/pdfMHRA Drug Safety Update March 2023 PDF.pdf (277KB)24/03/2023Download
 Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure. Terlipressin in patients with type 1 hepatorenal syndrome: new recommendations to reduce risks... 
application/pdfMHRA Drug Safety Update February 2023 DSU.pdf (206KB)27/02/2023Download
 This month on page 2 we summarise recent advice relating to COVID-19 vaccines and medicines published since the January 2023 issue of Drug Safety Update. And on page 3, we include recent letters,... 
application/pdfMHRA Drug Safety Update January 2023-DSU-PDF.pdf (255KB)26/01/2023Download
 The monthly newsletter from the Medicines and Healthcare products Regulatory Agency and its independent advisor the Commission on Human Medicines 
application/pdfMHRA Drug Safety Update December 2022 PDF.pdf (223KB)15/12/2022Download
 Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in the coming months. Valproate: reminder of current Pregnancy... 
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9]
[ Next » ]